H. Lundbeck Company Description
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia.
It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.
The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals.
It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies.
The company was founded in 1915 and is headquartered in Valby, Denmark.
| Country | Denmark |
| Founded | 1915 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 5,681 |
| CEO | Charl van Zyl |
Contact Details
Address: Ottiliavej 9 Valby, 2500 Denmark | |
| Phone | 45 36 30 13 11 |
| Website | lundbeck.com |
Stock Details
| Ticker Symbol | HLUBF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061804697 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Charl van Zyl | Chief Executive Officer |
| Joerg Hornstein | Chief Financial Officer |
| Palle Olesen | Head of Investor Relations |